Uptake, Efficacy, and Systemic Distribution of Naked, Inhaled Short Interfering RNA (siRNA) and Locked Nucleic Acid (LNA) Antisense

Sterghios Moschos(University of Westminster), Michael Yeadon(Pfizer (United Kingdom)), Diana Gikunju(Pfizer (United States)), Cris Lapthorn(Pfizer (United Kingdom)), Paul Turnpenny(Pfizer (United Kingdom)), Manfred Frick(Pfizer (United Kingdom)), Steve Evans(Pfizer (United Kingdom)), Karen G. Spink(Pfizer (United Kingdom)), Giuseppe Ciaramella(Pfizer (United Kingdom)), Eugen Uhlmann(Pfizer (Germany)), Gareth Jones(University of Bristol), Kevin Brady(Pfizer (United Kingdom)), Sarah Kearney(Pfizer (United Kingdom)), Lyn H. Jones(Pfizer (United Kingdom)), Romesh R. Subramanian(Pfizer (United States)), Houria Mechiche(Pfizer (United Kingdom)), Matthew D. Selby(Pfizer (United Kingdom)), Jürgen Vollmer(Pfizer (Germany)), Martin X Green(Pfizer (United Kingdom)), B Keith Taylor(Pfizer (United Kingdom)), David J. Collins(The University of Melbourne), Helen Graves(Pfizer (United Kingdom)), Ovadia Lazari(Pfizer (United Kingdom)), Marion Jurk(Pfizer (Germany)), Thomas Dino Rockel(Pfizer (Germany)), Sally A Fancy(Pfizer (United Kingdom)), Markus Weber(Pfizer (Germany)), David Lamb(Analog Devices (United States)), Luis Perez-Tosar(Pfizer (United Kingdom))
Molecular Therapy
October 4, 2011
Cited by 84


Related Papers